Research Article
Tumor Differentiation is the Dominant Prognostic Factor for Patients with Colorectal Neuroendocrine Neoplasms with Distant Metastasis
Table 2
Clinicopathological data between patients with metastatic colorectal NETs and NECs before and after propensity score matching.
| | Characteristic | Original cohort | Matched cohort | | NET (n = 35) | NEC (n = 42) | P | NET (n = 20) | NEC (n = 20) | P |
| | Sex, n (%) | | | 0.802 | | | 0.744 | | Male | 19 (54.3%) | 24 (57.1%) | | 13 (65.0%) | 12 (60.0%) | | | Female | 16 (45.7%) | 18 (42.9%) | | 7 (35.0%) | 8 (40.0%) | | | Age (years, mean ± SD) | 57.1 ± 2.0 | 58.9 ± 2.0 | 0.609 | 57.5 ± 2.7 | 58.97 ± 2.7 | 0.757 | | BMI (kg/m2, mean ± SD) | 24.3 ± 0.7 | 23.2 ± 0.5 | 0.189 | 23.5 ± 0.8 | 23.8 ± 0.6 | 0.828 | | Primary tumor location, n (%) | | | <0.001 | | | 1.000 | | Rectum | 32 (91.4%) | 23 (54.8%) | | 17 (85.0%) | 18 (90.0%) | | | Colon | 3 (8.6%) | 19 (45.2%) | | 3 (15.0%) | 2 (10.0%) | | | Primary tumor size, n (%) | | | 0.008 | | | 1.000 | | ≤2 cm | 12 (34.3%) | 4 (9.5%) | | 3 (15.0%) | 3 (15.0%) | | | >2 cm | 23 (65.7%) | 38 (90.5%) | | 17 (85.0%) | 17 (85.0%) | | | Primary tumor shape, (%) | | | 0.001 | | | 0.752 | | Ulcerative type | 24 (68.6%) | 13 (31.0%) | | 10 (50.0%) | 9 (45.0%) | | | Protrude type | 11 (31.4%) | 29 (69.0%) | | 10 (50.0%) | 11 (55.0%) | | | TNM T stage, n (%) | | | 0.009 | | | 1.000 | | T1 and T2 | 9 (25.7%) | 2 (4.8%) | | 1 (5.0%) | 1 (5.0%) | | | T3 and T4 | 26 (74.3%) | 40 (95.2%) | | 19 (95.0%) | 19 (95.0%) | | | TNM N stage, n (%) | | | 0.771 | | | 1.000 | | N0 | 5 (14.3%) | 4 (9.5%) | | 2 (10.0%) | 2 (10.0%) | | | N1 | 30 (85.7%) | 38 (90.5%) | | 18 (90.0%) | 18 (90.0%) | | | Extrahepatic metastasis, n (%) | | | 0.021 | | | 0.744 | | Yes | 15 (42.9%) | 29 (69.0%) | | 8 (40.0%) | 7 (35.0%) | | | No | 20 (57.1%) | 13 (31.0%) | | 12 (60.0%) | 13 (65.0%) | | | Synaptophysin, n (%) | | | 0.872 | | | 1.000 | | Positive | 33 (94.3%) | 41 (97.6%) | | 19 (95.0%) | 20 (100%) | | | Negative | 2 (5.7%) | 1 (2.4%) | | 1 (5.0%) | 0 (0) | | | CD56, n (%) | | | 0.065 | | | 1.000 | | Positive | 34 (97.1%) | 34 (81.0%) | | 19 (95.0%) | 18 (90.0%) | | | Negative | 1 (2.9%) | 8 (19.0%) | | 1 (5.0%) | 2 (10.0%) | | | Surgical resection, n (%) | 19 (54.3%) | 16 (38.1%) | 0.155 | 11 (55.0%) | 10 (50.0%) | 0.752 |
|
|
NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; SD, standard deviation; BMI, body mass index.
|
